Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas (Nasdaq: ARVN) held its fourth company-wide Impact Day on May 17, 2026, uniting employees across Connecticut, Greater Boston, and the U.S. in community service. Projects supported organizations including Ronald McDonald House, Fleece & Thank You, American Cancer Society Hope Lodge, Save the Sound, Boys & Girls Club, and Community Soup Kitchen.
Arvinas (Nasdaq: ARVN) reported Q1 2026 results and major milestones, including FDA approval of VEPPANU (vepdegestrant), the first approved PROTAC, for ESR1‑mutated ER+/HER2‑ advanced breast cancer and a global licensing deal with Rigel.
Q1 revenue was $15.6M versus $188.8M a year ago, mainly from Pfizer collaborations. GAAP R&D fell to $60.3M from $90.8M, and GAAP G&A to $19.1M from $26.6M. Cash and securities were $614.9M, expected to fund operations into 2H 2028. The company highlighted positive ARV‑102 Phase 1 biomarker data, multiple pipeline advances, and appointed Randy Teel as President and CEO.
Arvinas (Nasdaq: ARVN) and Pfizer signed a global license agreement granting Rigel exclusive rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA‑approved PROTAC.
Arvinas and Pfizer receive $70M upfront, $15M transition payments, up to $320M milestones, and mid‑teens to mid‑20s tiered royalties.
Arvinas (Nasdaq: ARVN) will report first quarter 2026 financial results on May 12, 2026 with a live webcast at 8:00 a.m. ET. Management will review Q1 results and provide a corporate update.
Investors can access the webcast under Events and Presentations on the Arvinas investor website; a replay will be posted after the event.
Arvinas (Nasdaq: ARVN) announced FDA approval of VEPPANU (vepdegestrant) on May 1, 2026, for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after progression on endocrine therapy. VEPPANU is the first FDA‑approved PROTAC. VERITAC-2 (n=270 ESR1m) showed a 43% risk reduction in PFS (HR 0.57); median PFS 5.0 vs 2.1 months. Approval occurred before the June 5, 2026 PDUFA date. Arvinas and Pfizer will select a third-party commercial partner. Important safety issues include QT prolongation and common lab abnormalities.
Arvinas (Nasdaq: ARVN) reported Phase 1 results for ARV-102 showing approximately ≥50% LRRK2 degradation in CSF by day 14, maintained through day 28, across 20–80 mg daily doses. ARV-102 showed dose-dependent CSF exposure, reduced endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB), and was generally well tolerated with no SAEs, supporting further development including a planned Phase 1b in PSP in Q2 2026.
Arvinas (Nasdaq: ARVN) will present Phase 1 human data for ARV-102, an oral PROTAC degrader targeting LRRK2, at AD/PD 2026 in Copenhagen. The presentation on March 18, 2026 at 3:30 PM CET covers safety, pharmacokinetics, and pharmacodynamics in participants with Parkinson’s disease.
Arvinas (Nasdaq: ARVN) reported 4Q and full‑year 2025 results and a corporate update on Feb 24, 2026. Key items: cash, cash equivalents and marketable securities of $685.4M at year‑end; cash runway into the second half of 2028; multiple clinical readouts and program milestones planned in 2026; Randy Teel named President and CEO.
Pipeline progress includes ARV‑102 AD/PD data in March 2026, ARV‑806 and ARV‑393 clinical updates in 2026, initiation of ARV‑027 healthy‑volunteer trial, and ARV‑6723 Phase 1 planned mid‑2026.
Arvinas (Nasdaq: ARVN) said management will participate in four investor conferences in early March 2026, including TD Cowen, Leerink Global Healthcare, Barclays Global Healthcare, and Jefferies Biotech on the Beach.
Each appearance is a fireside chat with specific times on March 3, 9, 10 and 11; replays will be posted in the Events and Presentations section of the company website.
Arvinas (Nasdaq: ARVN) will report fourth quarter and full year 2025 financial results on February 24, 2026. Management will review results and provide a corporate update via a live webcast at 8:00 a.m. ET.
The webcast is available under “Events and Presentations” on Arvinas’ investor website, and a replay will be posted on www.arvinas.com after the event.